Well, thank you. Deepak. Let's now review the financial results for the second fiscal quarter in greater detail. As mentioned previously, our revenues in Q2 of fiscal 2019 increased 9% year-over-year. Q2 revenues in the Security division increased by 10% from Q2 of last year, driven by growth in both cargo and vehicle inspection equipment sales and RTT. The 13% year-over-year revenue growth reported for our Opto division was driven by revenues from the Flex circuit businesses acquired in January 2018 and from our optical sensor and higher-level assemblies business acquired in July 2018, partially offset by a reduction in intercompany sales as inventory levels decreased as we focused on working capital management. As Deepak mentioned, we are pleased with the direction in the Healthcare division. Our revenue in the second fiscal quarter constituted the divisions' best quarterly performance for the 2018 calendar year. Revenues increased 2.5% year-over-year in our core patient monitoring, cardiology and supplies and accessories product lines. This increase was offset by the de-emphasis of sales in our anesthesia product line and in an underperforming sales channel that we exited during the second fiscal quarter, resulting in an overall 2% decrease in net revenues. Our Q2 gross margin of 36.4% was comparable to the 36.6% in Q2 of last year. We saw a gross margin expansion in each of our Opto and Healthcare divisions with a slight year-over-year reduction in the Security division gross margin. As mentioned on previous calls, our gross margin will fluctuate from period to period based on revenue mix among other factors. Moving to operating expenses. In Q2 of fiscal 2019, SG&A expenses were up $7 million over SG&A in the same period last year, primarily in the Security division and also due to the added expenses from the Opto division acquisitions. We continue to focus in all of our divisions on improving efficiencies, and prudently managing our cost structure. R&D expenses in Q2 were $12.8 million, down from Q2 of the prior year as was also the case for the last quarter. This was primarily due to efficiencies in our Security division from the post acquisition consolidation of operations of acquired businesses, and our Healthcare division from reductions of our de-emphasis on anesthesia products. We remain focused on innovative product development which we view is vital to the long-term success of our business. Impairment, restructuring and other charges were negative $1.3 million in Q2 of fiscal 2019 as compared to a positive $8.3 million in Q2 of fiscal 2018. The current year amount reflects a net insurance reimbursement of certain legal costs incurred which were partially offset by charges in our Healthcare division related to employee severance and the wind-down of sales channel costs. Moving to taxes. Excluding the impact of discrete tax items, the company's effective tax rate was 28.3% in Q2 of fiscal 2019, essentially unchanged from the rate in the prior year quarter. During the three months ended December 31st, 2018, we recognized a discrete tax benefit of approximately $400,000 resulting in a reported effective tax rate of 26.8%. During the three months ended December 31st, 2017, we recognized an approximate $56 dollar net discrete tax charge primarily from changes under the Tax Act. Let's now turn to a discussion on our non-GAAP adjusted operating margin, which excludes the items mentioned earlier in the call. The company's non-GAAP adjusted operating margin improved to 11.4% in Q2 of fiscal 2019 from 10.8% in Q2 of fiscal 2018. This increase was primarily driven by the strong performance of the Opto division and a favorable mix of higher margin revenue in our Security division. Looking on a sequential basis, the adjusted operating margin in the Healthcare division increased from negative 4.4% to positive 10.8% reflecting the significant progress in turning this business around. Moving a cash flow. In Q of fiscal 2019, we generated $43.7 million in operating cash flow. The strong cash flow was driven by increased profits and significant improvements in working capital. Collections were strong as Day Sales Outstanding or DSO decreased from 76 days in Q1 of this fiscal year to 68 days in Q2 of fiscal 2019. As mentioned on the last call, we had a big buildup of inventory in Q1 to support future shipments with strong Q2 sales and improved inventory management; inventory declined significantly contributing to the strong Q2 cash flow. Capital expenditures in the quarter were $4.8 million, while depreciation and amortization was $14.1 million. During Q2, we repurchased 184,170 at an average price of $71.59 per share for a total cost of $13.2 million. Under our current board authorization, we have approximately 562,000 shares remaining for potential repurchase. Our balance sheet remains strong. We ended the quarter with net leverage of approximately 1.9 as calculated under a revolving credit facility. Finally, turning to guidance. We are raising our fiscal 2019 sales guidance to a range of $1.150 billion to $1.185 billion and we are increasing our fiscal year 2019 non-GAAP earnings per diluted share guidance to $3.93 to $4.10. Note this guidance factors in start-up costs associated with the new turnkeys which occur in advance of recognizing revenue just like the past turnkey projects, as well as not quite as favorable margin mix in the Security division. This non-GAAP diluted EPS range excludes impairment, restructuring and other charges, amortization of acquired intangible assets and non-cash interest expense and their associated tax effects and discrete tax items. Additionally, we continue to evaluate the impact of tax reform on our effective tax rate including the effect of new taxes associated with computations for the Global Intangible Low Tax Income known as GILTI and Foreign -Derived Intangible Income known as FDII. Each of these provisions is complex. The effective tax rate is subject to significant volatility and will be updated as more analysis and information is available. We currently believe the sales and non-GAAP earnings guidance reflects reasonable estimates. Actual sales and earnings, however, could vary from the anticipated ranges due to the risks and uncertainties specifically affecting our business and generally affecting industries in which we operate. These risks and uncertainties include items beyond our control such as site readiness or product installations, evolving government trade policies, customer acceptance and a timing of orders in each division and other risks and uncertainties discussed in our SEC filings. We have continued to grow our business while investing in product development and making selective, strategic acquisitions. Our product and acquisition investments enable OSI to continue our leadership role with innovative products and solutions across our various industries. Thank you for participating in this conference call. And at this time we would like to open the call to questions.